Multicenter Study of Infectious and Noninfectious Endophthalmitis after Intravitreal Ranibizumab Injections

The intravitreal use of anti-vascular endothelial growth factor (anti-VEGF) agents has become the standard of care for the treatment of neovascular age-related macular degeneration (AMD). In particular, intravitreal ranibizumab (IVR) has been demonstrated to be very efficacious in different well-designed clinical trials [1,2]. It is also increasingly being used to treat other types of choroidal neovascularization (CNV) and macular edema of various etiologies [3-9]. Additionally, patients often require multiple periodic reinjections to achieve or maintain a therapeutic effect. Given both the widespread use of IVR and the potential need for frequent reinjections, the safety of these injections continues to be scrutinized.